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Available online 19 January 2014Vascular dementia (VaD) is a leading cause of dementia in the elderly together with
Alzheimer's disease with limited treatment options. Poor understanding of the
pathophysiology underlying VaD is hindering the development of new therapies. Hence,
to unravel its underlying molecular pathology, an iTRAQ-2D-LC–MS/MS strategy was used
for quantitative analysis of pooled lysates from Brodmann area 21 of pathologically
confirmed cases of VaD and matched non-neurological controls. A total of 144 differentially
expressed proteins out of 2281 confidently identified proteins (false discovery rate = 0.3%)
were shortlisted for bioinformatics analysis. Western blot analysis of selected proteins
using samples from individual patients (n = 10 per group) showed statistically significant
increases in the abundance of SOD1 and NCAM and reduced ATP5A in VaD. This suggested
a state of hypometabolism and vascular insufficiency along with an inflammatory
condition during VaD. Elevation of SOD1 and increasing trend for iron-storage proteins
(FTL, FTH1) may be indicative of an oxidative imbalance that is accompanied by an aberrant
ironmetabolism. The synaptic proteins did not exhibit a generalized decrease in abundance
(e.g. syntaxin) in the VaD subjects. This reported proteome offers a reference data set for
future basic or translational studies on VaD.
Biological significance
Our study is the first quantitative clinical proteomic study where iTRAQ-2D-LC–MS/MS
strategy has been used to identify the differential proteome in the VaD cortex by comparing
VaD and matched control subjects. We generate testable hypothesis about the involvement
of various proteins in the vascular and parenchymal events during the evolution of VaD
that finally leads to malfunction and demise of brain cells. This study also establishes
quantitative proteomics as a complementary approach and viable alternative to existingKeywords:
Vascular dementia
Clinical proteomics
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iTRAQ
Vascular dysfunction
Oxidative stressf Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore,
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55J O U R N A L O F P R O T E O M I C S 9 9 ( 2 0 1 4 ) 5 4 – 6 7neurochemical, electron microscopic and neuroimaging techniques that are traditionally
being used to understand the molecular pathology of VaD. Our study could inspire fellow
researchers to initiate similar retrospective studies targeting various ethnicities, age-groups
or sub-types of VaD using brain samples available from brain banks across the world.
Meta-analysis of these studies in the future may be able to shortlist candidate proteins or
pathways for rationale exploration of therapeutic targets or biomarkers for VaD.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Vascular dementia (VaD) is the secondmost common cause of
age-related dementia after Alzheimer's disease (AD) [1].
Significantly extended life expectancy coupled with the
sedentary lifestyle is predicted to increase the incidence of
type 2 diabetes, hypertension and hyperlipidemia, all of
which are risk factors for vascular disease and subsequent
vascular cognitive impairment. The worldwide number of
patients with vascular causes of dementia is expected to rise
assuming no effective prevention strategies or curative
treatments are developed and implemented [2].
Knowledge of VaDpathophysiology has been lagging behind
AD for a number of reasons. The lack of suitable animalmodels
and difficulties in obtaining well-characterized clinical sam-
ples has hampered the progress of basic and translational
research on VaD. Immunohistochemical, neurochemical and
electron microscopic studies using post-mortem clinical
samples remained the mainstay of mechanistic research
[3–5]. Neuroimaging together with clinical observation in
patients has provided vital complementary information that
forms the basis for the current understanding of VaD [6].
Multiple clinicopathologic substrates have been implicated
in the pathogenesis (e.g. cortical or subcortical microinfarcts,
demyelination of white matter, cribriform change of basal
ganglia and white matter) that links cerebrovascular changes
to cognitive impairment, independent of Alzheimer's type
pathology [7]. However, the molecular events that drive
these vascular and parenchymal changes in the brain are
still poorly understood. Given the complexity andheterogeneity
of cerebrovascular disorder and the presence of co-morbidities
in VaD patients, it is likely that rather than an individual or
small number of proteins, multiple candidate proteins present
in networks are perturbed leading to the spectrum of cognitive
and behavioral symptoms.
The advent of quantitative proteomic technologies using
isobaric labeling strategy has made it possible to quantify
several proteins in a single experiment for comparative study
of global protein regulation across various biological sam-
ples. Isobaric tag for relative and absolute quantification
(iTRAQ) is one of the most commonly used in vitro isotopic
labeling strategies in different areas of biological science and
medicine for simultaneously quantifying 4- or 8-plex sam-
ples [8]. Clinical proteomics of dementia have flourished in
the recent times with a rapid increase in the number of
studies analyzing different parts of the post-mortem brain of
AD patients for expression profiling studies [9,10]. Apart from
the well-known β-amyloid and tau hypothesis, the involve-
ment of pathological events such as excitotoxicity, oxidative
stress and inflammationhas beenhighlighted. Post-translational
modifications such as carbonylation and phosphorylationof various key proteins have also been found to contribute
to AD.
Despite having immense potential to elucidate disease
mechanisms, proteomic studies of VaD using preclinical or
clinical samples are lacking. Recently, we have successfully
applied an iTRAQ-based shotgun neuroproteomic strategy in
the area of ischemic stroke to study validated pre-clinical
models [11,12], and ischemic infarcts from autopsied human
brain [13]. Here, we apply a similar iTRAQ-two dimensional-
liquid chromatography–tandem mass spectrometry (iTRAQ-
2D-LC–MS/MS) based quantitative proteomic approach on
post-mortem VaD and matched non-demented control spec-
imens from Brodmann area 21(BA21) of the temporal lobe for
better understanding of the underlyingmolecular mechanism
of VaD. We focused on the temporal lobe because medial
temporal lobe atrophy is a common finding in dementia and
our recent study suggested that there is a vascular basis for
neurodegeneration [14]. The temporal lobe is also relatively
free of large infarcts thus making it ideal to detect the survival
response of the demented brain [15]. The iTRAQ experiment
identified differentially expressed proteins from the pooled
lysates of the two groups. Bioinformatics analysis of the
proteomic data set revealed the aberrant regulation of proteins
related tomultiple cellular or subcellular events associatedwith
VaD such as vascular dysfunction and oxidative stress. Some
representative deregulated proteins were further validated by
Western Blotting (WB) using individual patients. This study is
the first quantitative proteomic investigation to reveal the
differential global proteomes between VaD and age-matched
control brain that provide a valuable data set for future basic or
translational studies with individual proteins to propose
potential therapeutic targets or biomarkers of VaD.2. Materials and methods
2.1. Reagents
Unless indicated, all reagents and assay kits were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Patients and clinical assessments
We obtained frozen brain tissues from 10 non-demented
elderly controls and 10 age-matched VaD subjects. The tissues
were obtained from the Newcastle Brain Tissue Resource,
Institute for Ageing and Health, Newcastle University. Demo-
graphic details of the subjects are summarized in Table 1 and
can be found for individual subjects in the Supplemental
Table 1. For this study, we assessed samples of the grey and
white matter from BA21 area of the temporal lobe. VaD was
Table 1 – Demographics and disease variables for groups of control and VaD patients.
Demographics Control VaD
Number of cases 10 10
Age at death (mean yrs ± SD)a 80.3 ± 8.9 84.0 ± 8.5
Sex (male/female) 2 M/8 F 7 M/3 F
Duration of illness (yrs) na 3.8 ± 3.5
Post-mortem interval (median ± IQR)a 24.5 ± 24.0 36.5 ± 41.0
Disease variables
Pre-death MMSE (median ± SD/N) na 14.3 ± 3.7(6)
Braak staging (N) 0–II 5 9
III–IV 3 0
V–VI 0 0
NA* 2 1
SD, standard deviation; IQR, interquartile range. na, not applicable; *NA, Not available.
a The groups were not significantly different in terms of Age (independent sample t-test, p-value > 0.05) or post-mortem interval
(Mann–Whitney U test, p-value > 0.05).
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Disorders and Stroke and Association Internationale pour la
Recherché et l'Enseignement en Neurosciences criteria [16].
Pathological diagnosis of VaD was defined by the presence of
multiple or cystic infarcts involving cortical and sub-cortical
structures, border-zone infarcts, lacunae (<15 mm), micro-
infarcts (visible by microscopy only) and small vessel disease
in sub-cortical structures in the general absence of neurofibril-
lary tangles [15]. Clinical evidence of dementia along with the
same type or a combination of these lesions at three different
coronal levels was considered diagnostic for VaD. None of the
VaD cases exhibited tangle burden diagnostic for AD or more
than ‘sparse’ neuritic plaques as defined by Consortium to
Establish a Registry for Alzheimer'sDisease (CERAD) [17,18]. The
cognitive assessments were made using Mini-Mental StateFig. 1 – Schematic representation of experimental dExamination (MMSE) [19]. MMSE is a 30-point scale to evaluate
the cognitive functions that cover orientation, memory, and
attention. MMSE also includes the subject's ability to follow
verbal and written commands. All control subjects were
cognitively normal and they did not have any history of
dementia, neurological disease or psychiatric conditions. The
control participants did not qualify for the neuropathological
diagnostic criteria of ADas none of the subjects had higher than
Braak stage III/IV tangle burden or more than “sparse” plaque
counts by CERADcriteria. Demographic and disease variables of
the control and VaD patients indicated comparable samples for
analysis (Table 1; Supplemental Table 1).
Ethical approval was granted by local research ethics com-
mittees for this study (Newcastle upon Tyne Hospitals Trust, UK)
and permission for post-mortem research using brain tissuewasesign showing discovery and validation phase.
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obtained from the Institutional Review Board of the National
University of Singapore. Informed consent was also obtained
from the guardians of the patients prior to donation of brain
tissues.
2.3. Experimental design
The experimental design is described in Fig. 1 and Table 1.
Overall, it was divided into two phases, discovery phase and
validation phase. Themajor challenge of expression profiling
studies is to discriminate disease-specific changes from
individual variations. To discover a consensus proteomic
signature predictive of VaD and to gather enough amount of
starting material, equal weight of tissues were pooled group-
wise from 10 individual samples for the iTRAQ analysis in the
discovery phase. Pooling has been suggested to get rid of the
outliers or aberrant individual variations while highlighting
most consistent disease-specific changes [20]. The tryptic
digest from pooled control and VaD (n = 10 for each group)
samples were labeled by two iTRAQ tags (114: control, 115:
VaD) of the 4-plex iTRAQ kit. The iTRAQ experiment
was repeated thrice (experimental replicate = 3, iTRAQ-1,
iTRAQ-2, iTRAQ-3) using the pooled digest. Injection for LC–
MS/MS was performed thrice (technical replicate = 3)
for iTRAQ-1 and iTRAQ-2 and four times (technical replicate =
4) for iTRAQ-3 as multiple injections give better coverage of the
target proteome with superior statistical consistency [21].
Thus, a total of 10 (=3 + 3 + 4) MS injections were performed
to generate ten individual data sets that will allow for the
calculation of technical as well as experimental variations
arising from individual iTRAQ experiments. Post-proteomic
validation of selected proteins from the iTRAQ data set was
performed on individual patients (biological replicate = 10 for
control and VaD group) using a separate tissue specimen from
the BA21 area of the same individual byWBanalysis tomeasure
the extent of biological variation.
2.4. Proteomics
2.4.1. Sample preparation
Sample processing including centrifugation and sonication
were performed at 4 °C unless mentioned otherwise. A
biphasic chloroform/methanol extraction coupled with ace-
tone precipitation was adopted with slight modifications
as described previously [22,23]. This is to maximize the
recovery of various macromolecules and matabolites from
scarce clinical specimens suitable for downstream process-
ing through different -omics platforms. Briefly, equal quan-
tities of frozen tissues (w/w) were pooled in a group-wise
manner and grounded into fine powder using liquid nitrogen
before being suspended in a mixture of methanol (Merck
KGaA, Darmstadt, Germany), chloroform and water (J.T.
Baker, Center Valley, PA, USA) (1:1:2). The suspension was
mixed for 1 h and subsequently centrifuged (15 000 ×g,
2 min) to obtain the pellet. The non-polar chloroform
fractions were kept for separate studies. The previous step
was repeated using a mixture of methanol, chloroform and
water (4:1:3) for washing the pellet. The polar methanol–water
phase was combined from consecutive steps and mixed withacetone (overnight, 4 volumes of acetone, −20 °C) followed by
centrifugation (15 000 ×g, 5 min) to precipitate the residual
proteins. Methanol was used subsequently to wash the protein
containing pellets and remove contaminants that were followed
by centrifugation (15 000 ×g, 2 min). Protein pellets were
dissolved in 8 M urea with protease inhibitor cocktail
(Complete (Roche; Mannheim, Germany)) by intermittent
sonication for 20 s (amplitude, 30%) using a Vibra Cell high
intensity ultrasonic processor (Jencon Scientific Ltd.; Leighton
Buzzard, Bedfordshire, U.K.). It was subsequently centrifuged
(20 000 ×g for 30 min) to collect the supernatant. The protein
concentration of the supernatant was determined by the
bicinchoninic acid assay.
2.4.2. In-gel tryptic digestion and isobaric labeling
The samples (250 μg of proteins/condition) were then re-
duced (5 mM tris-(2-carboxyethyl) phosphine, 30 °C, 3 h) and
alkylated (20 mMmethylmethanethiosulfonate in isopropanol,
room temperature, 45 min in dark) followed by a two-step
digestion (16 h + 4 h) at 30 °C with sequencing-grade modified
trypsin (Promega, Madison, WI, USA) at a ratio of 1:100 (trypsin:
sample) in 50 mM triethylammonium bicarbonate (TEAB).
The tryptic digested peptides were desalted using Sep-Pak
C18 cartridges (Waters, Milford, MA, USA) and dried in a
vacuum centrifuge. The dried peptides were reconstituted
into 0.5 M TEAB and labeled with respective isobaric tags of
4-plex iTRAQ reagents (Applied Biosystems, Foster City, CA,
USA) as follows: control, 114; VaD, 115 (Fig. 1). The labeled
peptides were combined and dried in a vacuum centrifuge.
The iTRAQ sample was desalted using Sep-Pak C18 cartridges
and dried before fractionation. Three batches of experimen-
tal replicates were prepared separately as showed in the
experimental design.
2.4.3. Electrostatic repulsion and hydrophilic interaction
chromatography (ERLIC)
The mixture of iTRAQ-labeled peptides was fractionated
using a PolyWAX LP anion-exchange column (4.6 × 200 mm,
5 μm, 300 Å) (PolyLC, Columbia, MD, USA) on a Prominence
UFLC system (Shimadzu, Kyoto, Japan) and monitored at the
wavelength of 280 nm. Thirty five fractions were collected
during a 60 min gradient of 100% buffer A (0.1% acetic acid,
and 10 mM ammonium acetate in 85% acetonitrile (ACN)) for
5 min, 0–36% of buffer B (0.1% formic acid (FA) in 30% ACN) for
25 min, 36–100% of buffer B for 20 min, and 100% of buffer B
for the last 10 min at a flow rate of 1 ml/min [24,25]. Eluted
fractions were pooled into 26 fractions depending on the peak
intensities. They were dried in a vacuum centrifuge and
redissolved in 0.1% FA in 3% ACN for LC–MS/MS analysis.
2.4.4. Reverse phase LC–MS/MS analysis using QSTAR
Each fraction of redissolved iTRAQ-labeled peptides was
sequentially injected in triplicate and separated in a home-
packed nanobore C18 column with a picofrit nanospray tip
(75 μm ID × 15 cm, 5 μm particles) (New Objectives, Woburn,
MA, USA) on a Tempo nano-MDLC system coupled with a
QSTAR Elite Hybrid MS (Applied Biosystems/MDS-SCIEX).
Each fraction was independently analyzed by the LC–MS/MS
over a gradient of 90 min with the constant flow rate of
300 nl/min. Data acquisition in QSTAR Elite was set to
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Biosystems). The precursors with a mass range of 300–
1600 m/z and calculated charge from +2 to +5 were selected
for fragmentation. For each MS spectrum, 5 most abundant
peptides at most above a 5-count threshold were selected for
MS/MS, and the selected precursor was dynamically excluded
for 20s with a mass tolerance of 0.1 Da. Smart information-
dependent acquisition was activated with automatic collision
energy and automatic MS/MS accumulation. The fragment
intensity multiplier was set to 20 and maximum accumulation
time was 2 s.
2.4.5. Mass spectrometric raw data analysis
Spectra acquired from each of the technical and experimental
replicates were submitted alone and together to ProteinPilot
Software (v 3.0, Revision Number: 114 732, Applied Biosystems)
for peak list generation, protein identification and quantifica-
tion against the concatenated target-decoy Uniport human
database (downloaded on 12 March 2012). User defined param-
eters in ProteinPilot software were configured as described
previously [11] with minor modifications as follows: (i) Special
factors, urea denaturation; (ii) Specify Processing, quantitate,
bias and background correction. Default precursor and MS/MS
tolerance for QSTAR ESI-MS instrument were adopted auto-
matically by the software. The false discovery rates (FDR) of
both peptide and protein identification were set to be less than
1% (FDR = 2.0 * decoy_hits / total_hits).
2.4.6. Bioinformatics analysis
The open-source software Panther and David were used for
the enrichment analysis in various categories like Gene
Ontology and pathways by submitting Uniprot accession
numbers of the short-listed proteins [26,27]. The human
proteome was used as a default background for David. The
enrichment analysis in David identifies overrepresentation of
certain phenotype (i.e. a group of proteins common to a
specific pathway, class, location, function, disease or any
other attribute) from long list of regulated proteins that did
not occur only by chance. Significances were expressed by
fold of enrichment and p-value before and after corrections
with Benjamini–Hochberg or modified Fisher's exact test. Any
phenotype was considered enriched when the p-value was
less than 0.01 and FDR less than 1% after corrections with both
the above-mentioned methods.
2.4.7. Post-proteomic validation
2.4.7.1. Sample processing. The samples were briefly thawed
on ice and dissected to remove meninges and exclude the
blood vessels and the white matter. Cleaned samples were
then homogenized at 50 mg tissue/ml in an ice cold cell lysis
buffer (20 mM Tris–HCl, 150 mM NaCl, pH 7.5) (Cell Signaling
Technology, Danvers, MA, USA). Protease inhibitor cocktail
(Complete (Roche)) was added immediately before use. Protein
concentrationsweremeasured using a 2-DQuant kit (Amersham
Biosciences, Piscataway, NJ, USA).
2.4.7.2. WB analysis. WB was performed after SDS-PAGE by
probing with primary antibodies at the indicated dilutions:
anti-ACTB (beta-actin, 1:10000, mouse monoclonal; Millipore,Billerica, MA, USA), anti-BCL2 (B-cell CLL/lymphoma 2, 1:1000,
mouse monoclonal; Santa Cruz Biotech, Santa Cruz, CA, USA),
anti-ferritin (1:4000, rabbit polyclonal; Abcam, Cambridge,
UK), anti-HSPA4 (heat shock 70 kDa protein 4, 1:5000, mouse
monoclonal; Abcam), anti-ICAM5 (intercellular adhesion
molecule 5, 1:1000, rabbit polyclonal; Abcam), anti-NCAM
(neural cell adhesion molecule, 1:10000, rabbit polyclonal;
Santa Cruz Biotech), anti-PEA15 (phosphoprotein enriched
in astrocytes, 1:800, rabbit polyclonal; Abcam), anti-SOD1
(superoxide dismutase 1, 1:2000, rabbit polyclonal; Abcam),
anti-syntaxin (1:10000, mouse monoclonal; Milipore), anti-
SYNPO (synaptopodin, 1:1000, rabbit polyclonal; Abcam) and
anti-VDAC1 (voltage-dependent anion channel 1, 1:5000,
mouse monoclonal; Santa Cruz Biotech). Immunoblotting
of ACTB was used as a loading control. Apart from that, two
commercially available antibody cocktails were used; Mitoprofile
Total OXPHOS Human WB Antibody Cocktail (1:2000, mouse
monoclonal, MS601; Mitoscience, Eugene, Oregon) andApoptosis
Western Blot Cocktail (1:250, MS1107; Mitoscience). MS601
consisted of five antibodies targeting key proteins of oxidative
phosphorylation (i.e. NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 8, mitochondrial (NDUFB8); Cytochrome c
oxidase subunit 2 (MT-CO2), Succinate dehydrogenase [ubi-
quinone] iron–sulfur subunit, mitochondrial (SDHB); Cyto-
chrome b-c1 complex subunit 2, mitochondrial (UQCRC2)
and ATP synthase subunit alpha, mitochondrial (ATP5A)).
MS1107 detects 32 kDa pro-caspase 3, 17 kDa active caspase 3,
89 kDa apoptosis-specific cleaved Poly [ADP-ribose] polymerase
1 (PARP) along with muscle actin which is incorporated as a
loading control. This cocktail does not react with full-length
PARP. Twenty to forty micrograms of proteins were used for
WB depending on the sensitivity of the specific antibody.
Immunoreactivity was detected by using an HRP chemilumi-
nescent substrate reagent kit (Invitrogen, Carlsbad, CA). A
pooled sample was used to normalize the inter-gel variation
between repeated runs for the same protein.
2.4.7.3. Statistical analysis. All statistical analyses were
performed using SPSS 13.0 for Windows software (SPSS Inc.).
Normality of data was first checked using the Kolmogorov–
Smirnov test. Independent sample t-test was used to compare
the means of control and VaD group. Equal variances were
assumed for the calculation of p-values as the two groups had
equal number of subjects (n = 10). Non-parametric Mann–
Whitney U Test was used for comparing non-normal distribu-
tions. Correlations involving only continuous data (i.e. age,
post-mortem interval, andprotein abundance)were analyzedby
Pearson's product moment correlation. Spearman's rank corre-
lation was used when one of the variables are ordinal in nature
(i.e. MMSE score, Braak staging, and CERAD score). Experimental
data for WB analysis were presented as mean ±SEM. Statistical
significance was accepted at *p < 0.05 and **p < 0.01.3. Results
To understand the global proteomic change in VaD, pooled
tissue extracts were compared between groups of age-matched
control and VaD subjects by iTRAQ experiment.
Fig. 2 – Percent variation in iTRAQ ratios (115/114) between the
same protein found in various technical and experimental
replicates following MS. The primary vertical axis represents
the corresponding number of the proteins (bars) having
different % co-efficient of variation (%CV) that was plotted in
the horizontal axis. The secondary vertical axis represents the
cumulative % of the counted proteins (lines) where 100%
equals to 1878 proteins. These proteins have confidently been
identified in at least 3 out of 10MS runs. Ninety eight percent of
the proteins had less than 40% of %CV. Accordingly; the
regulation cut-off was set at 1.4-fold.
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A strict cut-off of unused ProtScore ≥ 2 was used as the
qualification criteria to minimize the false positive identifica-
tion of proteins. With this criteria, 1569, 2039 and 1525
proteins were identified from the three iTRAQ experiments
with a FDR of <0.8%. To improve the confidence of identifica-
tion and quantification, all ten individual injections from the
three iTRAQ experiments were combined for subsequent
analysis. The combined data set had 2281 proteins with a
FDR of 0.3% using the ProtScore cut-off mentioned above
(Supplemental Table 2). The average number of unique
peptides (having a confidence level of ≥95%) detected per
protein was 21.8. More than 55% of the proteins (1260
proteins) had ≥5 unique peptides, while around 14% of
proteins were identified with a single peptide. The average %
coverage for the combined data set was 28.2%, whereas
around 39.4% of the proteins (901 proteins) had % coverage
more than the average level. Intriguingly, some proteins
were identified with 100% sequence coverage (e.g. Hemoglo-
bin subunit beta (HBB), Gamma-synuclein, and Fructose-
bisphosphate aldolase C) (Supplemental Table 2). This result
is better than our previously published report where a single
iTRAQ experiment was performed to study the regulated
proteome [12]. To the best of our knowledge, this data set is
likely the biggest neuroproteomics data set from similar
iTRAQ based quantitative clinical proteomic study. Next, the
ratios were sorted using a p-value cut-off of 0.05 to shortlist a
set of 171 significantly perturbed proteins for further analysis.
3.2. Estimation of threshold for confidently defining
perturbed proteins
To determine the cut-off for up- or down-regulation, the
deviation of ratios (i.e. 115/114) of individual proteins between
various technical and experimental replicates were measured
as described previously [11,12]. The proteins that have been
confidently identified in at least 3 injections were included.
Accordingly, geometric mean, standard deviation and %coef-
ficient of variation (%CV) of 1878 proteins were determined.
The average %CV was around 13%. The %CV was less than
20% and 40% for more than 84% and 98% of the proteins
(Fig. 2). Based on this, the regulation threshold was set at
1.4 fold; ratio >1.40 or <0.71 was considered as up- or down-
regulated respectively. Applying this threshold to the 171
significantly perturbed proteins, a list of 144 proteins (6.3%
of initial hits) was obtained; where 72 each were up- and
down-regulated (Supplemental Table 3). This was advanced to
the next stage for bioinformatics analysis to retrieve hidden
biological trends.
3.3. Bioinformatics analysis
Bioinformatics analysis revealed up-regulation of various
neurotransmitter signaling pathways (e.g. glutamate and
acetylcholine) while glycolysis, tricarboxylic acid cycle, ATP
synthesis and pyruvate metabolism were featured among
the down-regulated pathways. Recently, the up-regulation of
GluR2 subunit of glutamatergic α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptorwas reported in the BA22 areaof the VaD brain when compared with age-matched control and
mixed AD/VaD cases, which is concordant with the trends
observed in our study [28]. Proteins related tometabolic, immune
system process, cell adhesion and apoptosis exhibited mixed
trends. Majority of metabolic proteins (77.9%, 60/77) were
decreased in theVaDbrain,while proteins linked to cell adhesion
(90.9%, 10/11) and immune system processes (61.1%, 11/18) were
elevated. This is consistent with a recent RNAmicroarray study
reporting the up-regulation of genes associated with cell
adhesion and immune response in the deep subcortical
white matter lesion [29]. The levels of most of the perturbed
extracellular proteins (87.5%, 7/8) including FGB, COL6A3,
NCDN, VCAN, andNFASCwere increased. Among the perturbed
protein classes, the calcium binding proteins (80%, 4/5; SLC25A3,
SPTBN2, SPTBN1, PLEC) and chaperones (71.4%, 5/7; HSPB1,
HSPA5, STIP1, CCT8, TBCA) were mainly elevated while all
proteases (5/5; e.g. NPEPPS, PREP and PSMA6) were reduced in
the VaD brain. Finally, guided by the above trends, the selected
list of proteins was manually classified into various functional
categories with additional proteins taken from the complete
data set based on their relevance with the respective categories
(Table 2).
3.4. Post-proteomic validation by WB analysis
Eleven proteins (i.e. SOD1, NCAM, ATP5A, UQCRC2, SYNPO,
HSPA4, VDAC1, ferritin, PEA15, ICAM5 and syntaxin) were
selected from the list of 171 significantly regulated proteins for
validation in twenty subjects individually (Fig. 3). They were
selected from a wide range of molecular functions according
to the bioinformatics analysis, such as energy metabolism
(e.g. ATP5A, UQCRC2), oxidative stress (e.g. SOD1, ferritin),
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(e.g. SYNPO, syntaxin) and apoptosis (e.g. HSPA4, PEA15,
VDAC1). In addition, three more candidates (i.e. SDHB, MT-CO2
and NDUFB8) related to oxidative phosphorylation were also
included as negative control to check the reliability of the relative
quantization as none of them were significantly (p > 0.05)
regulated in the proteomics result (Table 2). It should be noted
here that unlike iTRAQ experiment, which was performed on
pooled lysates, the p-value in the WB analysis is an estimate
of the biological variation based on the cohort of twenty
individuals.
The abundance of SOD1 (p = 0.014) and NCAM (p = 0.018)
was significantly higher whereas ATP5A (p = 0.047) and
UQCRC2 (p = 0.006) were significantly lower in VaD compared
to the controls. SYNPO (p = 0.062), HSPA4 (p = 0.100) and
VDAC1 (p = 0.168) showed a decreasing trend unlike ferritin
(p = 0.192), PEA15 (p = 0.114) and ICAM5 (p = 0.578) that
showed an increasing trend in the VaD group. A poor p-value
for WB analysis is related to higher individual variation in the
expression of a protein within the same group. Hence,
increasing the number of subjects per group could have
resulted in a statistically significant difference for some of
the above mentioned candidates. Considering the groups
were not gender-matched, individual abundances of all
proteins from WB results were compared between male
(n = 9) and female (n = 11) to evaluate the influence of
gender as a potential confounding factor. The levels of
UQCRC2 were found to be significantly lower (p = 0.027) in
male compared to female subjects thus excluding it from
further discussion.
Syntaxin did not exhibit any difference between VaD and
control groups byWB, although it was found to be up-regulated
(i.e. STX1A and STX1B, ~1.8 fold) in the iTRAQ analysis (Table 2).
This ambiguity can be related to the sampling of an indepen-
dent piece of tissue for proteomic and WB validation experi-
ment or may have arisen from the different sample processing
protocols. The three negative controls (SDHB, MT-CO2 and
NDUFB8) did not show difference between VaD and control
brain tissues in bothWB and iTRAQ, indicating the reliability of
the sample pooling strategy in the discovery phase. Overall, a
consistent trend was observed with the iTRAQ result for the
selected proteins with the exception of syntaxin.
3.5. Correlation analyses
One of the major confounding factors for studies involving
post-mortem specimens of geriatric subjects is sampling
artifact that may alter pattern or magnitude of protein
expression [30]. Correlation analysis was performed for two
groups of subjects individually and in combination in order to
study linear associations between the immunoreactivities of
the key perturbed proteins and available neuropathological or
clinical variables. Individual abundances of none of the
proteins used for WB validation correlated with age or post-
mortem interval of the recruited subjects thereby excluding
the presence of systematic bias related to the sample
collection. Moderate to strong correlations were obtained in
between the abundances of various proteins selected for
validation. Notably, immunoreactivities of two significantly
elevated proteins in the VaD brain (i.e. SOD1 and NCAM) werepositively correlated with various mitochondrial proteins
such as VDAC1 (SOD1, r = 0.86, p < 0.01), SDHB (SOD1, r =
0.76, p < 0.05; NCAM, r = 0.65, p < 0.05), and MT-CO2 (SOD1,
r = 0.71, p < 0.05; NCAM, r = 0.80, p < 0.01) and were negatively
correlated with the synaptic protein, syntaxin (SOD1, r = −0.77,
p < 0.05; NCAM, r = −0.69, p < 0.05). No association was found
between the protein levels andMMSE scores for the VaD group.
Detailed results of the correlation analysis can be found in the
Supplemental Table 4.4. Discussion
To our knowledge, this is the first comparative proteomic
profiling of post-mortem brain tissues of VaD and control
subjects by combining the attributes of biphasic chloroform/
methanol extraction for sample preparation, multiplex iso-
baric labeling with iTRAQ reagent chemistry, two dimensional
liquid chromatography, nano-electrospray ionization and
high resolution tandem mass spectrometry (iTRAQ-2D-LC–
MS/MS).
4.1. Unraveling the pathophysiology of VaD — a systems
biological perspective
To ensure specificity of dementia due to vascular causes and
not due to the presence of co-morbidities, extensive neuro-
pathological characterization was performed to exclude
confounding from two other possible causes of dementia
(e.g. AD and dementia with Lewy bodies (DLB)). VaD samples
did not exhibit significant Alzheimer's type of pathology as
the neuritic plaques were confined to only the entorhinal
areas (stage I–II) (Table 1). These stages are generally considered
to be without symptoms or be associated with little evidence of
dementia [31]. Additionally, immunoreactivity of none of the
tested fourteen candidates' correlated with the Braak staging
(n = 17), MMSE score (n = 7) and CERAD score (n = 10) thus
excluding probable etiological association between key
perturbed proteins with Alzheimer's pathology (Supplemen-
tal Table 4). Neuropathological examination also confirmed
the absence of Lewy body pathology in the selected subjects
(data not shown). Hence, the presence of cognitive impair-
ment as seen by the low MMSE scores in the VaD group
(Table 1) was associated with cerebrovascular pathology
through the deregulation of different functional classes of
proteins found in the current data set.
4.2. Cortical hypoperfusion and vascular dysfunction in VaD
The plasma proteins in our short-listed data set may allow
better understanding of the perfusion status of the brain in
VaD subjects. The significantly up-regulated list of proteins in
the proteomic data set was dominated by different isoforms of
immunoglobins (e.g. IGHA1, IGHG2, IGSF8, IGLC2 and IGKC)
and other known plasma proteins (e.g. FGB). Intriguingly, HBB
was the protein with maximum fold of down-regulation. HBD
also showed significant down-regulation albeit with lesser
magnitudes (Table 2, Fig. 4). Hemoglobins (i.e. HBB and HBD)
generally remained entrapped in the erythrocytes, which does
Table 2 – Significantly regulated proteome of VaD selected from the complete list of confidently identified proteinsa.
N Unused %Cov
(95)
Gene
symbol
Name Peptides
(95%)
VaD: Control
(115:114)
EF†
(115:114)
Energy metabolism
Glycolysis
16 214.6 96.1 ENO1 Alpha-enolase 517 1.74 1.15
18 212.7 99.7 ALDOA Fructose-bisphosphate aldolase A 421 0.53 1.19
27 179.8 99.8 PGK1 Phosphoglycerate kinase 1 296 0.47 1.31
43 124.9 100.0 ALDOC Fructose-bisphosphate aldolase C 298 0.54 1.20
150 56.2 66.8 LDHB L-Lactate dehydrogenase B chain 74 0.60 1.16
311 33.7 64.2 LDHA L-Lactate dehydrogenase A chain 30 0.52 1.29
Pyruvate dehydrogenase complex
332 32.2 31.3 PDHA1 Pyruvate dehydrogenase E1 component
subunit alpha, somatic form, mitochondrial
19 0.61 1.19
355 30.5 49.9 PDHB Pyruvate dehydrogenase E1 component
subunit beta, mitochondrial
37 0.58 1.21
395 27.2 29.5 DLAT Dihydrolipoyllysine-residue acetyltransferase
component of pyruvate dehydrogenase
complex, mitochondrial
20 0.34 1.57
Tricarboxylic acid cycle
51 113.1 68.1 ACO2 Aconitate hydratase, mitochondrial 139 0.46 1.38
118 65.2 60.6 IDH2 Isocitrate dehydrogenase [NADP], mitochondrial 39 0.35 1.45
222 42.8 63.9 FH Fumarate hydratase, mitochondrial 40 0.44 1.50
253 39.1 56.6 IDH3A Isocitrate dehydrogenase [NAD] subunit alpha,
mitochondrial
26 0.62 1.19
324 32.7 40.2 SUCLG1 Succinyl-CoA ligase [ADP/GDP-forming]
subunit alpha, mitochondrial
35 0.49 1.31
565 20.0 31.5 SUCLA2 Succinyl-CoA ligase [ADP-forming]
subunit beta, mitochondrial
12 0.51 1.26
Oxidative phosphorylation
41 130.1 72.7 ATP5A1 ATP synthase subunit alpha, mitochondrial 124 0.57 1.26
42 129.9 80.5 ATP5B ATP synthase subunit beta, mitochondrial 191 0.52 1.20
168 51.9 77.8 ATP5J ATP synthase-coupling factor 6, mitochondrial 64 1.75 1.19
178 49.9 40.4 NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa
subunit, mitochondrial
35 0.49 1.36
193 47.6 55.4 DLD Dihydrolipoyl dehydrogenase, mitochondrial 29 0.53 1.26
202 45.6 61.6 UQCRC2 Cytochrome b–c1 complex subunit 2, mitochondrial 36 0.53 1.36
274 37.7 78.9 ATP5O ATP synthase subunit O, mitochondrial 29 0.51 1.45
340 31.8 45.7 SDHB Succinate dehydrogenase [ubiquinone]
iron–sulfur subunit, mitochondrial b
22 0.72 1.13
1232 6.2 19.4 MT-CO2 Cytochrome c oxidase subunit 2b 4 1.06 1.21
1260 6.1 28.0 NDUFB8 NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 8, mitochondrialb
4 0.95 1.15
Vascular dysfunction and inflammation
17 214.3 92.1 ALB Serum albumin 235 2.03 1.29
30 161.4 100.0 HBB Hemoglobin subunit beta 356 0.26 1.39
126 62.3 31.3 L1CAM Neural cell adhesion molecule L1 56 1.49 1.12
157 53.7 38.0 NCAM1 Neural cell adhesion molecule 1 37 1.79 1.32
256 38.7 31.8 ICAM5 Intercellular adhesion molecule 5 31 1.75 1.21
265 38.1 27.8 FGA Fibrinogen alpha chain 25 2.23 1.53
326 32.5 57.8 IGHA1 Ig alpha-1 chain C region 24 5.55 2.36
383 28.3 47.5 IGHG2 Ig gamma-2 chain C region 20 4.02 1.84
419 26.0 96.6 HBD Hemoglobin subunit delta 152 0.54 1.21
442 25.2 26.8 IGSF8 Immunoglobulin superfamily member 8 15 2.13 1.46
461 24.2 47.9 FGB Fibrinogen beta chain 15 1.94 1.46
609 18.4 74.5 IGLC2 Ig lambda-2 chain C regions 13 3.77 1.96
734 14.5 90.6 IGKC Ig kappa chain C region 20 4.41 2.17
1256 6.1 3.0 COL6A3 Collagen alpha-3(VI) chain 8 1.79 1.29
Synaptic transmission
9 266.6 99.8 ENO2 Gamma-enolase 586 1.58 1.14
26 181.9 98.4 PEBP1 Phosphatidylethanolamine-binding protein 1 342 1.57 1.17
119 65.0 39.9 ATP1A3 Sodium/potassium-transporting ATPase
subunit alpha-3
45 2.96 1.53
121 63.7 80.1 RPS27A Ubiquitin-40S ribosomal protein S27a 55 3.87 1.74
133 60.1 43.8 SYNPO Synaptopodinb 46 0.73 1.10
141 58.2 52.8 PPP3CA Serine/threonine-protein phosphatase
2B catalytic subunit alpha isoform
52 0.57 1.27
(continued on next page)
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Table 2 (continued)
N Unused %Cov
(95)
Gene
symbol
Name Peptides
(95%)
VaD: Control
(115:114)
EF†
(115:114)
218 43.3 49.2 ABAT 4-Aminobutyrate aminotransferase, mitochondrial 26 0.59 1.21
244 40.1 40.5 ALDH9A1 4-Trimethylaminobutyraldehyde dehydrogenase 29 0.56 1.26
345 31.6 65.0 SNAP25 Synaptosomal-associated protein 25 34 1.64 1.20
358 30.3 36.5 STX1B Syntaxin-1B 23 1.89 1.29
463 24.1 14.3 SLC1A2 Excitatory amino acid transporter 2 22 2.63 1.51
667 16.5 29.5 STX1A Syntaxin-1A 9 1.85 1.26
783 13.3 26.0 ATP1A2 Sodium/potassium-transporting
ATPase subunit alpha-2
32 2.21 1.60
Oxidative stress
63 99.0 99.3 SOD1 Superoxide dismutase [Cu–Zn] 188 3.02 1.72
134 59.8 82.5 FTH1 Ferritin heavy chain 135 2.05 1.41
152 55.4 63.4 FTL Ferritin light chain 80 2.21 1.41
208 44.5 85.7 PRDX6 Peroxiredoxin-6 48 0.41 1.45
279 37.2 84.7 GPX1 Glutathione peroxidase 1b 30 1.18 1.13
898 11.0 14.2 GSR Glutathione reductase, mitochondrialb 8 0.63 1.26
Chaperonic function
70 90.8 60.9 HSPA5 78 kDa glucose-regulated protein 94 1.42 1.12
72 88.6 61.1 HSP90AA1 Heat shock protein HSP 90-alpha 79 0.43 1.45
92 76.2 67.2 STIP1 Stress-induced-phosphoprotein 1 61 1.45 1.15
132 60.2 53.5 HSPA4 Heat shock 70 kDa protein 4 40 0.46 1.42
255 38.7 96.1 HSPB1 Heat shock protein beta-1 63 1.77 1.17
330 32.3 44.0 CCT8 T-complex protein 1 subunit theta 19 1.80 1.29
656 17.0 80.6 TBCA Tubulin-specific chaperone A 16 1.57 1.20
Others
71 90.6 37.6 NFASC Neurofascin 72 1.75 1.26
73 87.9 96.1 VDAC1 Voltage-dependent anion-selective channel protein 1 91 0.56 1.17
84 80.6 100 SNCG Gamma-synucleinb 91 1.08 1.04
200 46.0 33.4 NPEPPS Puromycin-sensitive aminopeptidase 27 0.42 1.47
203 45.4 97.7 PEA15 Astrocytic phosphoprotein PEA-15 42 1.56 1.15
651 17.2 15.1 PREP Prolyl endopeptidase 10 0.58 1.20
799 12.8 37.4 PSMA6 Proteasome subunit alpha type-6 8 0.64 1.26
The gene symbols of the proteins selected for WB validation are shown in bold. The proteins have been classified based on their respective
primary function/pathway. The energy metabolism category is sub-divided into four groups. Majority of the proteins related to energy
metabolism were down-regulated, while proteins related to inflammation (immune response and cell adhesion) were up-regulated. Proteins
participating in synaptic transmission and chaperonic function displayed a mixed trend.
a The list of proteins qualified through the preset selection criteria (unused prot score > 2.0, p < 0.05, regulation cut-off : 1.4 fold compared to
the control group) along with their relative quantitative values. The gene symbols of the proteins selected for WB validation are shown in bold.
The proteins have been classified based on their respective primary function/pathway. The energymetabolism category is sub-divided into four
groups. Majority of the proteins related to energy metabolism were down-regulated, while proteins related to inflammation (immune response
and cell adhesion) were up-regulated. Proteins participating in synaptic transmission and chaperonic function displayed a mixed trend.
b Proteins incorporated in the list due to their close association with the regulated proteins although they did not meet the above-mentioned
preset selection criteria. For example, the fold of down-regulation was <1.4 fold for SYNPO, while others (e.g. SDHB, SNCG) doesn't have a
significant p-value (i.e. p > 0.05).
†EF; error factor. It is a measure of the certainty of the average ratio. The true ratio for the protein is expected to be found between (reported
ratio) ÷ EF and (reported ratio) * EF for 95% of the time.
Synaptic transmission
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hemorrhage. The decreased presence of hemoglobin may be
indicative of a perfusion failure in the VaD cortex along with a
diffuse leakage of the blood brain barrier (BBB) that is
manifested by an apparent increase in the levels of several
proteins of circulatory source. In addition, we observed
significant down-regulation of a key component of oxidative
phosphorylation (i.e. ATP5A) while HSPA4 and mitochondrial
protein VDAC1 showed down-ward trends during WB valida-
tion indicating a state of hypometabolism and mitochondrial
failure (Fig. 3). Further, the up-regulation of an isoform ofcollagen (i.e. COL6A3) in the iTRAQ result may indicate
accumulation of extracellular matrix components that could
cause collagenosis and vascular stenosis thus aggravating the
perfusion failure [32]. The unraveled molecular events from
our unbiased quantitative proteomic study may offer a
mechanistic explanation for previous observations from
neuroimaging and neuropathologic studies. The disruption
of BBB in small vessel disease has been documented using
dynamic contrast-enhanced magnetic resonance imaging in
live patients and through immunohistochemistry of immu-
noglobulins and fibrinogen of brain tissue [33,34]. Cortical
Fig. 3 – Post-proteomic validation of the selected proteins using
individual patients from control and VaD groups by WB
analysis. Equal amount of protein was loaded as measured by
the 2D Quant kit. A) Representative immunoblots showing the
protein levels in B21 area of all twenty patients (n = 10 per
group). Details of the patients can be found in the Supplemental
Table 1. ACTB was used as a loading control. B) Bar chart of
densitometric analysis for comparing the protein expression
levels by the statistical analysis. SOD1 and NCAM were
significantly increased whereas ATP5A was reduced signifi-
cantly in the VaD brain. Trends were observed for SYNPO,
HSPA4, VADC1, ferritin, PEA15 and ICAM5 without reaching a
statistical significance. Data was presented asmean ± SEM (n =
10), where *p < 0.05, significantly different from control using
independent-sample t-test.
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functional imaging like positron emission tomography in
patients of VaD in comparison with healthy controls [35] and
by two-dimensional xenon-133 inhalation technique in the
ipsilateral fronto-parietal cortex in the presence of sub-
cortical infarcts [36].
Considering chronic leakage of fluid and macromolecules,
a likely consequence will be induction of an inflammatory
response in the temporal cortex of VaD brain. Subsequently,
curating the proteomic data set for other hallmarks of inflam-
mation identified few adhesionmolecules (e.g. L1CAM, NCAM1,
ICAM5) showing an up-regulation in the VaD group (Table 2,Figs. 3, 4). The decrease inHSPA4,whichnormally functions as a
chaperone and protects cells from inflammation during cere-
bral ischemic injury, may further worsen the inflammatory
condition [37]. The levels of L1CAMandNCAMwere found to be
higher in the cerebrospinal fluid (CSF) of VaD, AD and MIX
dementia patients compared to non-demented controls [38].
Soluble form of ICAM5 has been detected in the serum within
the first 48 h of cerebral hypoxic–ischemic injury ofmice, where
shredded neuronal ICAM5 could act as an anti-inflammatory
agent by suppressing the T-cell activation [39,40].
4.3. Deregulation of iron metabolism and oxidative stress
In the human brain, iron is ubiquitous and is responsible for
the activity of key enzymes (e.g. cytochromes, mitochondrial
non-haem iron proteins) and for the synthesis of neurotrans-
mitters. Most of the total iron in a healthy brain is sequestered
by ferritin thus limiting its pro-oxidant potential. Brain
ferritin-associated iron levels increase with age. Abnormal
elevation of brain iron and ferritin has been reported in the
neurodegenerative dementias (i.e. AD, PD and dementia with
Lewy Bodies) suggesting that increased iron levels may
contribute to the misfolding and subsequent deposition of
key proteins [41]. Although consistent correlation between
iron accumulation and cognitive dysfunction has been
documented in animal or clinical studies related to neurode-
generative diseases like AD, similar reports are scarce in the
area of VaD [42]. Here, we report an increase of brain ferritin
(H- and L-isoforms) levels of VaD patients compared to the
age-matched control group (Table 2, Fig. 3). Interestingly, out
of the tested fourteen candidates for validation, only the
levels of ferritin (r = 0.76, p < 0.05) positively correlated with
the duration of illness in the VaD group (n = 8) indicating a
probable increase in iron accumulation along with the
progression of VaD (Supplemental Table 4).
Considering that increased level of ferritin may help the
demented brain to adapt against the oxidative stress by
capturing the free iron, the significant up-regulation of SOD1
in VaD brain could have a complementary protective role.
SOD1 catalyzes the dismutation of superoxide anion (O2−) into
oxygen and hydrogen peroxide (H2O2). The O2− can react with
ferric iron (Fe3+) by Haber–Weiss reaction to produce ferrous
iron (Fe2+) which further reacts with H2O2 by Fenton reaction
to generate highly reactive and damaging hydroxyl radical
(OH−) (Fig. 5). Hence, both ferritin and SOD1 could work in
tandem to remove ferrous iron (Fe2+) and O2− radicals thereby
preventing oxidative injury in the demented brain. Neverthe-
less, we also observed an upward trend for GPX in the
proteomic data set, an enzyme that reduces H2O2 to water
using reduced glutathione (GSH). Several studies with animal
models of ischemic stroke (focal or global cerebral ischemia)
have demonstrated the neuroprotective potential of SOD1
[43]. In line with that, we have seen reduced levels of SOD1
and elevated levels of ferritin in the ischemic infarcts (i.e. core
of injury), when compared with matched control subjects [13].
Recently, SOD1 has been selected to genetically modify neural
stem cells as its overexpression has improved their survival
following intracerebral administration in rodent models of
ischemic stroke. This is consistent with the probable protec-
tive role of SOD1 as discussed above [44].
Fig. 4 – Schematic diagram showing the interplay of various vascular and parenchymal events during the evolution of VaD. ↑,
up-regulation; ↓, down-regulation.
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Inflammatory and oxidative stress mechanisms as dis-
cussed above are suggested to precede apoptosis that finally
causes cell death in the demented brain [7,29]. Recent
studies have demonstrated neuronal apoptosis as one of
the contributing pathways of cell death in the neocortex of
cerebral autosomal-dominant arteriopathy with subcortical
infarcts and leukoencephalopathy [45]. Hence, to elucidate
the pathways that seal the fate of the stressed cells in this
group of VaD patients, we had tested the expression of
well-known apoptotic markers that include pro-caspase 3,
p17 subunit of active caspase 3, cleaved PARP along with
anti-apoptotic BCL2 protein. Pro-caspase 3 forms activated
caspase 3 at the initiation of apoptotic cascade that proteolyt-
ically cleaves the DNA repair enzyme, PARP to generate the
89 kDa apoptosis-specific PARP fragment. However, no signifi-
cant differential expression of pro-caspase-3 and BCL2 between
VaD and control subjects was observed (Fig. 6). The PARP
fragment and p17 subunit of caspase 3 remained undetected inFig. 5 – Schematic diagram showing the probable involvement
of SOD1 and ferritin (FTL, FTH1) in detoxifying the demented
brain cells from iron overload and oxidative imbalance.either group following WB analysis indicating the absence of
significant degradation of the PARP enzyme by active caspase 3.
Therefore, our data points toward the involvement of non-
apoptotic pathways of cell death in the cortex of the studied
VaD patients. However, there is tantalizingly little data on the
underlying mechanisms of cell death in VaD and the participa-
tion of autophagy has been speculated [7].
Overall, our quantitative proteomic approach documents
the up-regulation of seemingly protective and deleterious
pathways simultaneously in the temporal cortex of theFig. 6 – A. Representative immunoblots showing the levels
of important markers of apoptosis in the temporal cortex of
control and VaD patients. B. Bar chart of band densities (in
arbitrary units) involving all twenty individuals and
normalized with the expression of muscle actin, which
was used as a loading control. There were no statistically
significant difference in the abundance of BCL2 and pro-caspase
3 between control and VaD group. Data was presented as
mean ± SEM (n = 10), where *p < 0.05, significantly different
from control using independent-sample t-test.
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vascular insufficiency (e.g. HBB) and a decline in the energy
metabolism (i.e. ATP5A1) are accompanied by the up-ward
trend for anti-inflammatory (i.e. ICAM5), anti-apoptotic protein
(i.e. PEA15) or proteins related to iron storage (i.e. FTL, FTH1) or
anti-oxidative function (i.e. SOD1) (Fig. 4). This penumbra-like
condition is not surprising considering the presence of pre-
dominant sub-cortical lesions in these VaD subjects as we
deliberately sampled one neocortical area (i.e. BA21) that is
located at a distance from the epicenter of the vascular injury.
Accordingly, the synaptic proteins (e.g. syntaxin) did not showa
unanimous reduced expression indicating no generalized
synaptic decline as seen in the case of AD affected brain [5].
Hence, our proteomic result was able to identify the key
molecular substrates behind different pathological processes
that work in concert to cause the demise of the brain cells in
VaD. Further studies on larger cohort of patients and with
pre-clinical models could better explain these aberrant regula-
tions and their interactions with the existing supportive
therapies of VaD like cholinesterase inhibitors, antioxidants or
vasodilators.5. Limitations
Being a study performed using PM specimens; the data
interpretation is limited by the availability of samples. The
groups were not matched by sex and gender was found to be
a confounding factor for one of the candidate proteins (i.e.
UQCRC2) shortlisted for WB validation. However, all other
proteins including pro-caspase-3 and BCL2 did not show
significant difference between male and female groups. The
age of onset of VaD is variable among individuals along with
their different lifestyle and genetic backgrounds. Details of
co-morbidities, risk factors, medications and exact cause of
death are not available. Despite these limitations, they had
similar clinical and neuropathological presentations in a
group-wise manner that made the proteomic comparison of
pooled samples of identical brain location possible.
Our experimental design did not include groups of subjects
with clinically or biochemically overlapping pathologies such
as AD, DLB or ischemic stroke for a comparative validation of
the short-listed candidates. Hence, our conclusions are neces-
sarily limited to VaD as we are unable to comment on the
specificity of the reported candidates in the context of other
dementias or degenerative diseases. It would be worthwhile to
follow up the current work with samples from other types of
dementia to address the question of individual protein's
specificity to the pathology of interest.
Although confident identification of around 10% of
human proteome indicates the analytical sensitivity of the
current experimental design, cellular or subcellular locali-
zation and distribution of the regulated proteins among
different cell-types are not clear from our experiment. We
tried to partially address this by selecting relatively
cell-type specific candidates (e.g. PEA15, SYNPO, syntaxin)
for data interpretation and validation. Immunohistochem-
ical studies on similar samples targeting some of the
regulated candidates will be complementary to this
approach.6. Conclusions
Our quantitative clinical proteomic study demonstrates
deregulated proteome of the temporal cortex of VaD patients
compared to non-demented control subjects. We have suc-
cessfully applied novel sample preparation methods compat-
ible with the systems approach to confidently identify 2281
proteins by iTRAQ experiment using a group-wise sample
pooling strategy. The majority of the deregulated proteome
has never been reported in context of VaD or dementia. In
addition, we were able to obtain statistically significant
difference of three candidate proteins (SOD1, NCAM and
ATP5A) between VaD and control brain based on the WB
analysis of twenty individual subjects. Some of the key
proteins that play crucial roles in the progressive parenchy-
mal and vascular changes during VaD, like cortical hypoper-
fusion, hypometabolism, inflammation and oxidative stress
were identified in a single experiment. The parallel aberrant
regulation of multiple proteins may indicate an early degen-
erative changes or an actively ongoing adaptive process that
can only be captured by a systems biological tool like
proteomics. The tissue samples represent the most proximal
source to determine the pathologic alteration of proteome
that could eventually be reflected in the CSF or plasma. Thus,
the up-regulated proteome could provide a list of potential
candidates for future exploration of biomarkers from body
fluids by targeted analysis in clinically similar cohorts of VaD
patients. Detailed understanding of these pathologic events
and their correlation with dementia and cerebrovascular
pathology through follow-up studies could provide potential
therapeutic targets for VaD.Conflict of interest
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